MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-07-2026
Evogene Ltd. Operating Cash Flow 2011-2026 | EVGN
Annual Operating Cash Flow Evogene Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -24.7 M | -19.5 M | -17.7 M | -15.2 M | -15.9 M | -11.7 M | -12.4 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -11.7 M | -24.7 M | -16.7 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 0.79 | -1.15 % | $ 4.31 M |  China |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K |  USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.49 | 0.58 % | $ 1.04 B |  Canada |
 |
Frequency Therapeutics
FREQ
|
-78.6 M | - | - | $ 528 M | USA |
 |
argenx SE
ARGX
|
-607 M | $ 700.45 | -1.19 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.6 | 1.41 % | $ 8.66 B |  Australia |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Grifols, S.A.
GRFS
|
597 M | $ 7.81 | -2.01 % | $ 6.83 B |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 225.98 | -1.32 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-233 M | $ 4.13 | -5.06 % | $ 105 M |  Schweiz |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-22.3 M | - | 10.36 % | $ 9.8 M | USA |
 |
BioCardia
BCDA
|
-9.97 M | $ 1.26 | -0.79 % | $ 26.7 M | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
|
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-1.79 M | $ 14.2 | -0.7 % | $ 208 M | USA |
 |
Aptose Biosciences
APTO
|
-36 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 91.19 | 1.21 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-206 M | $ 1.44 | -1.37 % | $ 367 M | Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 6.68 | -4.57 % | $ 183 M |  Israel |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
-57.3 M | - | - | $ 521 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 7.92 | 1.67 % | $ 1.31 B | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.54 | -5.22 % | $ 16 M | USA |
 |
Certara
CERT
|
96.3 M | $ 6.67 | 1.6 % | $ 1.07 B | USA |
 |
Athira Pharma
ATHA
|
-97.2 M | - | - | $ 269 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 3.6 | -4.0 % | $ 7.83 B | Israel |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.09 M | - | -2.5 % | $ 5.88 M | USA |